INROADS, Abbreviated Title: Intelence aNd PRezista Once A Day Study



Status:Archived
Conditions:HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:November 2009
End Date:July 2012

Use our guide to learn which trials are right for you!

A Multicenter, Single Arm, Open-Label Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients


This study is a Phase II single arm, open-label, multicenter, study of 50 human
immunodeficiency virus-1 (HIV) infected adult patients, all of whom will receive etravirine
(ETR) 400mg and DRV/r 800/100mg each given orally once daily. This trial is designed to
evaluate the efficacy of the aforementioned ARV regimen, as measured by the percentage of
patients with HIV RNA <50 copies/mL at 48 weeks, in early treatment-experienced HIV-infected
patients. In addition to general safety parameter measurements, this trial will also assess
changes in metabolic, inflammatory, immune restoration, and bone markers. Screening will
occur over a 6-week period. The primary endpoint will be assessed at Week 48, and the
treatment period is 48 weeks. The end of study endpoint will be met by either completing the
Week 48 visit, or by early termination from the study for any reason.


This study is a Phase II single arm, open-label, multicenter, (all people involved know the
identity of the intervention) study of 50 HIV-1 infected adult patients, all of whom will
receive ETR 400mg and darunavir (DRV)/r 800/100mg each given orally once daily. This trial
is designed to evaluate the efficacy of the aforementioned ARV regimen, as measured by the
percentage of patients with HIV ribonucleic acid (RNA) <50 copies/mL at 48 weeks, in early
treatment-experienced HIV-infected patients. In addition to general safety parameter
measurements, this trial will also assess changes in metabolic, inflammatory, immune
restoration, and bone markers. Screening will occur over a 6-week period. The trial schedule
includes a Baseline Visit (Day 1), Open-label Treatment Phase (Weeks 4, 8, 12, 16, 20, 24,
30, 36, 42, 48/ Early Withdrawal) and a Post-treatment Phase (4 Week Follow-Up) visit. In
addition, all patients will have two pharmacokinetic (PK) samples drawn at Weeks 4 and 24, A
single PK sample will be drawn at Weeks 12, 36, and 48 (or early withdrawal visit). There
will also be a substudy conducting 24 hour intensive PK at week 4 for a subset of patients.
For patients who consent, genotyping for CYP2C9 and CYP2C19 will be performed at Baseline. A
Modified Medication Adherence Self-Report Inventory (M-MASRI) questionnaire will be
collected, which is a patient-reported survey to assess adherence to medication taking. The
primary endpoint will be assessed at Week 48, and the treatment period is 48 weeks. The end
of study endpoint will be met by either completing the Week 48 visit, or by early
termination from the study for any reason. ETR 400mg once daily for 48 weeks and DRV 800mg
once daily for 48 weeks.


We found this trial at
9
sites
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Atlanta, Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials
Celebration, Florida
?
mi
from
Celebration, FL
Click here to add this to my saved trials
Charlotte, North Carolina
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Detroit, Michigan
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Mountlake Terrace, Washington
?
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials
West Orange, New Jersey
?
mi
from
West Orange, NJ
Click here to add this to my saved trials